Targeting eosinophils in allergy, inflammation and beyond

Abstract

Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic disorders such as asthma and allergy, as well as diseases that are not primarily associated with eosinophils, such as autoimmunity and malignancy. Eosinophil-targeted therapeutic agents that are aimed at blocking specific steps involved in eosinophil development, migration and activation have recently entered clinical testing and have produced encouraging results and insights into the role of eosinophils. In this Review, we describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight strategies for using personalized medicine to treat eosinophilic disorders.

DOI: 10.1038/nrd3838
05010020132014201520162017
Citations per Year

380 Citations

Semantic Scholar estimates that this publication has 380 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Fulkerson2013TargetingEI, title={Targeting eosinophils in allergy, inflammation and beyond}, author={Patricia C. Fulkerson and Marc E Rothenberg}, journal={Nature Reviews Drug Discovery}, year={2013}, volume={12}, pages={117-129} }